Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2024 17:08 ET | Source: Abliva AB

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host...
May 13, 2024 08:30 ET | Source: Abliva AB

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today...